SCHEMBL25370604

SCHEMBL25370604

CCc1cc(C(F)(F)F)ncc1S(=O)(=O)N1CC2(CN(C3CC4(COC4)C3)C2)C1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
TRPV4 Q9HBA0 2/20 0.32
CYP2C9 P11712 1/20 0.31
IDO1 P14902 1/20 0.31
RORC P51449 2/20 0.30
SCN10A Q9Y5Y9 1/20 0.30
PSEN1 P49768 3/20 0.30
PSEN2 P49810 3/20 0.30
APH1B Q8WW43 3/20 0.30
NCSTN Q92542 3/20 0.30
APH1A Q96BI3 3/20 0.30
PSENEN Q9NZ42 3/20 0.30
PIK3CD O00329 1/20 0.30
PIK3CG P48736 1/20 0.30
CYP11B2 P19099 1/20 0.30
MGAT2 Q10469 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26065682 0.87 PSEN1 (0.37) TRPV4PSEN1PSEN2APH1BNCSTN
SCHEMBL25371598 0.85 CNR2 (0.35) ALOX5APFEN1PSEN1PSEN2APH1B
SCHEMBL30567040 0.85 CNR2 (0.35) ALOX5APFEN1PSEN1PSEN2APH1B
SCHEMBL25370537 0.82 TRPV4 (0.35) TRPV4RORCPSEN1PSEN2APH1B
SCHEMBL31416568 0.82 ALOX5AP (0.32) ALOX5APFEN1
SCHEMBL25372096 0.82 TRPV4 (0.35) TRPV4RORCPSEN1PSEN2APH1B
SCHEMBL25370535 0.82 TRPV4 (0.35) TRPV4RORCPSEN1PSEN2APH1B
SCHEMBL26065681 0.80 CYP2C9 (0.31) CYP2C9IDO1
SCHEMBL31416634 0.78 ALOX5AP (0.33) ALOX5APFEN1PIK3CDPIK3CGCYP11B2
SCHEMBL25368306 0.78 PSEN1 (0.40) RORCPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 US claimed
EP-4482587-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-01-01 EP claimed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 WO claimed
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 US disclosed
EP-4482587-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-01-01 EP disclosed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP ALOX5AP 1485/4885FEN1 1742/4885TRPV4 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.